Tropharma

Quick links to important sections

Tropharma

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tropharma

Property Description
Active ingredient Erythromycin, Erythromycin Stearate
Form Film-coated tablet (Oral dosage form)
Pharmacological class Macrolide antibiotic, Anti-infective
General purpose To fight bacterial infections
Origin Semi-synthetic

Tropharma is a prescription medicine fundamentally defined as an anti-infective and classified under the specific group of macrolide antibiotics. Its primary purpose is to fight infections caused by susceptible bacteria by limiting their growth, a general benefit achieved by its targeted action within the bacterial cell. Erythromycin, the active component, is identified as a representative agent of this pharmacological class and is clinically recognized for its efficacy against several common bacterial strains, which means it provides a proven defense against various infectious agents. A typical use scenario for this class involves managing respiratory tract infections where susceptible organisms are identified.


Composition and Form: Erythromycin and the Stearate Salt

The core active compound in Tropharma is Erythromycin, which is present as both the base and the chemically altered Erythromycin Stearate, defining it as a single-entity product. This medicine is delivered as an oral dosage form, specifically a film-coated tablet. Tropharma's origin is semi-synthetic, as Erythromycin is derived from the natural product of the bacterium Saccharopolyspora erythraea. The formulation includes the Stearate salt because this chemical modification is crucial for enhancing the stability of the active ingredient, ensuring the drug can survive the stomach's acidic environment and be effectively absorbed into the bloodstream for systemic action. This salt form is utilized to improve the absorption characteristics of the medicine when administered orally. This improved stability means the patient receives a more consistent and reliable dose of the active ingredient, a key feature differentiating it from less stable formulations.

Regulatory References

  1. Erythromycin Stearate

What side effects are possible with Tropharma?

Possible Side Effects and Safety Information

The safety profile for Tropharma, based on authoritative government regulatory documents, includes adverse reactions categorized by frequency and the body system affected (System-Organ Class or SOC).

Common and Less Common Adverse Reactions

The most commonly reported adverse events for Tropharma and its class of medicine are related to the Gastrointestinal disorders SOC, often including nausea, vomiting, abdominal pain, and diarrhea. These effects may be classified as Common (1/100 to <1/10) in official labeling.

Less frequent but documented adverse reactions involve other SOCs, such as Hepatobiliary disorders (liver enzyme elevations, jaundice) and effects on the Nervous system.

Serious and Clinically Significant Safety Information

Official regulatory information highlights the potential for serious adverse reactions, particularly those affecting the heart and liver:

  • Cardiac Risks: The drug has been associated with QT interval prolongation, an electrical abnormality of the heart that can lead to a potentially fatal irregular heart rhythm called Torsades de pointes (TdP). Patients with pre-existing heart conditions or those taking other QT-prolonging medications may be at increased risk.
  • Liver Injury: Cases of hepatotoxicity (liver damage), sometimes accompanied by cholestatic jaundice, have been documented.
  • Drug Interactions: The medicine is restricted due to significant interactions with other drugs metabolized by the CYP3A4 pathway, which can lead to severe toxicities, including colchicine toxicity and rhabdomyolysis.

Population-Specific and Exposure-Related Safety Notes

Certain risks are specific to patient populations or timing of exposure:

  • Infants: Use in newborns, particularly those under six months of age, has been associated with the risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).
  • Elderly Patients: Older patients may have an increased susceptibility to the drug's effects on the QT interval.
  • Prolonged Effect: Severe diarrhea, specifically Clostridioides difficile-associated diarrhea (CDAD), has been reported to occur during therapy or even up to two months following the discontinuation of the medicine.

All documented safety information, including frequency classifications, serious risks, and specific restrictions, is derived directly from official government regulatory documents (e.g., FDA, EMA) to define the full risk profile of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Tropharma (Erythromycin) overdose describes specific clinical manifestations and mandates immediate emergency action.

Overdose presentations commonly include severe gastrointestinal symptoms, such as nausea, vomiting, diarrhea, and abdominal cramping. Auditory system manifestations, including transient hearing loss (deafness) and tinnitus, have also been documented, particularly with high-dose exposure. The most serious and potentially fatal documented outcomes are cardiovascular toxicities, specifically QT interval prolongation and Torsades de Pointes (a type of irregular heart rhythm), which require immediate monitoring.

Required Emergency Actions

Action/Condition Official Regulatory Statement
Immediate Help Individuals must get medical help right away or call emergency services/Poison Control upon taking too much Tropharma.
Supportive Care Treatment is strictly symptomatic and supportive, and no specific antidote is known. Procedures such as gastric lavage may be considered.
Special Considerations Patients with pre-existing renal or hepatic impairment are at a higher documented risk for reversible hearing loss during overdose.

Continuous monitoring for cardiac and electrolyte changes is required in an overdose situation. The regulatory guidance confirms that any suspected overdose mandates contacting emergency services immediately due to the documented potential for severe cardiac complications.

Therapeutic Uses of Tropharma

What Tropharma Treats: Main Uses and Benefits

Tropharma (Erythromycin) is used for managing a range of infections caused by susceptible bacteria, focusing on alleviating the associated symptoms and providing therapeutic alternatives for specific patient needs. The medication is commonly applied across conditions presenting with acute or disruptive symptom patterns caused by bacterial proliferation.

This antibiotic is used in addressing conditions that include specific respiratory infections (such as Atypical Pneumonia, Legionnaires' Disease, and Whooping Cough), bacterial skin and soft tissue infections, and urogenital infections like Chlamydia. It also serves as a therapeutic alternative for penicillin-allergic patients and may be used as part of symptomatic management to help reduce the risk of recurrence of conditions such as Rheumatic Fever.

Tropharma is relevant for easing symptoms that interfere with daily comfort and may help reduce the overall symptom burden when bacterial infections create noticeable physiological strain. This medication assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms, especially when acute manifestations temporarily interfere with daily routines.

Quick Fact: Relief for Respiratory and Dermatological Discomfort
Tropharma is relevant for easing symptoms that interfere with daily comfort, such as the persistent coughing of Pertussis and the inflammatory lesions associated with bacterial skin infections.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tropharma? (Official Regulatory Information)

Official regulatory documents strictly define the population groups eligible for Tropharma (Erythromycin) use based on pre-existing conditions and concurrent medications.

Absolute Contraindications (Must Not Use)

Tropharma is contraindicated and must not be used in individuals with a known hypersensitivity to erythromycin or any macrolide antibiotic. It is also prohibited for patients with a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de Pointes, or those with uncorrected hypokalaemia or hypomagnesaemia. Eligibility is further restricted by concomitant use: the medicine is contraindicated if a patient is taking certain drugs, including simvastatin or lovastatin (statins), ergotamine, dihydroergotamine, or certain medications known to prolong the QT interval (e.g., cisapride, astemizole, terfenadine).

Restricted and Conditional Use

Caution is required when administering Tropharma to patients with impaired hepatic function or pre-existing liver disease, as the drug is primarily processed by the liver. Caution is also advised in patients with moderate to severe renal impairment due to a documented increased risk of ototoxicity (hearing loss).

Age and Life Stage Eligibility

  • Pediatric Use: Tropharma is approved for children; however, caution is advised in neonates and infants due to the reported risk of Infantile Hypertrophic Pyloric Stenosis (IHPS), especially during the first 14 days of life. Some tablet forms are not for use in children under 8 years.
  • Pregnancy/Lactation: Use during pregnancy is generally not recommended unless clearly needed. Erythromycin is excreted into human milk, requiring caution during lactation.

What should I know about interactions with other medicines?

Interaction scope

Tropharma's interaction profile is primarily defined by its documented status as a Cytochrome P450 3A4 (CYP3A4) inhibitor. This mechanism leads to increased plasma concentrations of numerous co-administered medicines, including certain statins, triazolobenzodiazepines (e.g., Midazolam, Triazolam), Oral Anticoagulants (e.g., Warfarin), and drugs such as Theophylline and Digoxin.


Interaction-related restrictions

Regulatory documents formally list several combinations as contraindicated. These include co-administration with Pimozide and agents that prolong the QT interval (e.g., Astemizole, Cisapride) due to the risk of serious cardiac events. Combination with Ergotamine or Dihydroergotamine is also prohibited due to the risk of acute ergot toxicity, characterized by vasospasm.


Timing and Population Notes

The official profile includes constraints on administration timing. Certain formulations should be taken in the fasting state to optimize absorption. The drug requires avoidance during and for two weeks after treatment with potent CYP3A4 inducers like St John's Wort. Caution is advised for patients with impaired hepatic function and the elderly.


Connection to the overall interaction profile

The interaction structure is defined by two critical parameters: the pharmacokinetic mechanism of CYP3A4 inhibition and the pharmacodynamic risk of additive QT prolongation, which together necessitate formal restrictions on use with specific cardiovascular and neurologic agents.

Mechanism of Action

The mechanism of Tropharma (Erythromycin) is defined by its selective interference with essential processes unique to susceptible bacteria, resulting in the inhibition of bacterial proliferation.

Targeted Inhibition of Pathogenic Protein Synthesis

This domain covers the drug's molecular action as an inhibitor that targets the 50S ribosomal subunit within the bacterial cell. By binding to the 23S rRNA in the ribosomal exit tunnel, Erythromycin physically blocks the elongation of new protein chains, triggering a mechanistic cascade that immediately arrests the pathogen's primary growth process.

Functional Arrest of Bacterial Replication

The immediate consequence of blocking protein synthesis is a bacteriostatic effect, meaning the bacteria's ability to divide and replicate is functionally halted. This physiological arrest leads to a reduction of the pathogenic load. The resulting reduction in pathogen load facilitates immune system clearance by reducing the pathogen's ability to proliferate exponentially.

Constraints Imposed by Mechanistic Evasion

The drug's functional mechanism is biologically limited by bacterial resistance, such as target site modification (methylation of the ribosomal binding site) and active efflux (pumping the drug out of the cell). These evasion mechanisms prevent the drug from reaching or binding its target, which functionally constrains the overall ability of Tropharma to suppress bacterial proliferation.

Dosage and Administration Information

How to use Tropharma

Tropharma (Erythromycin Stearate) is administered exclusively via the oral route as a film-coated tablet, with available strengths typically comprising 250 mg and 500 mg. The administration protocol is designed to maintain consistent levels of the anti-infective agent within the body.

The total daily amount of medicine for adults generally ranges from 1 gram to 4 grams, which is taken in divided doses throughout the day. A common starting pattern involves administering the dose every six hours, though frequency can vary based on the specific regimen. For severe infections, the maximum recommended daily amount reaches 4 grams.

A crucial aspect of the drug’s use involves the condition of intake: the tablets should be administered in a fasting state—at least 30 minutes before or two hours after a meal—to achieve optimal bioavailability. The duration of the treatment course depends on the clinical scenario, but for specific infections such as those caused by Streptococcus, the course is a minimum of 10 days. Use in pediatric patients is typically calculated based on body weight, ranging from 30 to 50 mg per kilogram of body weight per day, also administered in divided intervals throughout the day.

Recent Clinical Evidence

Research evidence / Overview of studies for Tropharma


Evidence for use in Chronic Insomnia

Research into Tropharma for chronic insomnia has primarily involved short-term studies, mainly randomized controlled trials (RCTs), which were applied in studies examining patient-reported experiences of sleep. These studies typically monitored outcomes related to sleep parameters, such as the time it took for participants to fall asleep, and patient-reported outcomes describing perceived discomfort related to poor sleep. Findings describe patterns observed in the studies where some short-term trials reported differences were observed in the measured time to fall asleep and in the total reported sleep time compared to control groups. However, evidence remains limited and heterogeneous, and these findings describe how patients reported their experience over the brief study periods.

The duration of most research exploring short-term symptom changes was limited to only a few weeks. The existing evidence contributes to understanding symptom patterns only within this narrow timeframe.


Evidence for use in Generalized Anxiety Disorder (GAD)

Tropharma was evaluated in research exploring how symptoms change over time for individuals diagnosed with Generalized Anxiety Disorder. Studies monitored outcomes reflecting daily functioning or activity level, primarily by tracking changes on standardized anxiety rating scales. Research describes that in the observed populations, some trials reported that average anxiety scores changed during the study period, with some reports indicating differences were observed in standardized anxiety scores compared to the starting point. These studies were generally short to moderate in duration, and data show patterns related to symptom intensity or variability within these timeframes.


What is Still Uncertain About Tropharma

A number of gaps remain in the research exploring Tropharma. Sample sizes were modest in many trials, and follow-up durations were limited, which impacts the certainty of the findings. The findings were heterogeneous across studies, and mixed results were reported in some areas. Data are still emerging, particularly for the potential use of Tropharma in conditions characterized by fluctuating or episodic manifestations. Comparative evidence is lacking against a broad range of other evaluated treatments. Research does not determine whether an individual will respond similarly to the group patterns observed, and further research is ongoing to address these open questions.

Frequently Asked Questions (FAQ)

Common questions about Tropharma (FAQ)


Q: What is Tropharma used for besides the main condition?

A: Official documents describe Tropharma as an anti-infective medicine. Its primary use is to treat or prevent a range of infections caused by susceptible bacteria, including those affecting the lower respiratory tract, skin, and certain other specific conditions like Listeriosis. This information comes from the official prescribing label.

Q: Is Tropharma a long-term treatment or short-term?

A: Tropharma is generally prescribed for a specific, defined course to resolve a bacterial infection. Official instructions stress the importance of completing the full course as directed, even if the patient feels better early.

Q: If I miss a dose of Tropharma, what happens?

A: If a dose is forgotten, official guidance describes taking it as soon as it is remembered, unless it is nearly time for the next scheduled dose. In that situation, the instruction is that the missed dose should be skipped. The regulatory protocol states that two doses should not be taken at the same time.

Q: Does Tropharma cause weight gain or weight loss?

A: Official adverse event reports for Tropharma's active ingredient, Erythromycin, list loss of appetite as a commonly reported side effect. There are no reports in regulatory documents suggesting the drug causes weight gain.

Q: Are the side effects of Tropharma permanent?

A: The most common side effects are generally temporary and subside when the medicine is discontinued. However, official safety information documents rare, but potentially long-lasting, effects like hearing loss and severe diarrhea (C. difficile-associated diarrhea), which may occur even months after discontinuing the medicine.

Q: Is there a list of foods or drinks to avoid while using Tropharma?

A: Yes, official instructions state that the tablets are prescribed to be administered in a fasting state to achieve optimal absorption. Additionally, regulatory information advises caution with grapefruit juice and avoiding dairy products or calcium-fortified foods near the time of dosing, as these may interfere with absorption.

Q: Is Tropharma the same type of medicine as [similar competing drug name]?

A: Official documents classify Tropharma as a macrolide antibiotic. While other medicines may belong to the same class, the active ingredient in Tropharma (Erythromycin) is distinct. The key difference between medicines within a class is the specific active ingredient and formulation.

Q: Why did my doctor choose Tropharma over other options?

A: Tropharma is described for use when an infection is proven or strongly suspected to be caused by susceptible bacteria. The final selection of medication is a clinical decision based on the specific infection and patient profile.

Q: Does Tropharma interact with alcohol?

A: Regulatory resources document an interaction with alcohol, noting that consumption may increase the risk of gastrointestinal side effects and potentially reduce the antibiotic's effectiveness.

Q: Can older adults use Tropharma safely?

A: Official safety information advises caution, noting that elderly patients may be more susceptible to drug-associated effects on the QT interval, which is a measure of heart rhythm. Caution is also noted for increased anticoagulant effects when used with Warfarin in the elderly.

Q: Does Tropharma have a black box warning from the FDA?

A: The official FDA-approved label for Erythromycin does not include a Black Box Warning. However, the label does contain prominent Warnings and Precautions regarding the potential for serious heart rhythm changes (QT interval prolongation) and severe diarrhea (C. difficile-associated diarrhea).

Q: What should I do if I accidentally take too much Tropharma?

A: Taking one extra dose is unlikely to cause serious harm, though it may increase temporary side effects. Official guidance states that if more than one extra dose is taken, contact with a healthcare professional should be sought immediately.

Q: Does Tropharma affect birth control pills?

A: Some official resources note that erythromycin may interfere with the body's recycling of certain hormonal contraceptives, potentially reducing their effectiveness. The risk is generally considered low, but official advice recommends consulting the specific product labeling for clarity.

Q: Are there any generic versions of Tropharma available?

A: Yes, the active ingredient in Tropharma, Erythromycin Stearate, is a long-established medication. Official FDA databases confirm that multiple generic versions have been approved and are available for use.

Q: What is the difference between Tropharma and a supplement?

A: Tropharma is classified as a prescription medicine and an antibacterial drug approved for treating or preventing infections caused by bacteria. Supplements are non-prescription products that are not regulated by the FDA or similar bodies to treat, diagnose, or prevent disease.

Q: Is Tropharma safe to use if I have a liver condition?

A: Official documents state that caution is required when the medicine is administered to patients with impaired hepatic function (liver condition). This is because the drug is primarily processed and excreted by the liver, and serious liver injury has been documented.

Q: Does Tropharma affect sleep patterns?

A: Research evidence has examined sleep-related outcomes, with some trials reporting that differences were observed in the measured time it took participants to fall asleep and in the total reported sleep time when compared to control groups.

Q: How does the effectiveness of Tropharma compare to placebo in studies?

A: Research summaries for conditions outside of its main use, such as anxiety and insomnia, report that differences were observed in measured outcomes (like standardized anxiety scores or time to fall asleep) when Tropharma groups were compared to control groups (which includes placebo). The evidence remains limited and heterogeneous.

Q: What is the purpose of the different strengths of Tropharma tablets?

A: Tropharma is available in different strengths (e.g., 250 mg and 500 mg) to allow healthcare providers to prescribe a total daily dose to be taken in divided intervals throughout the day. This is done to ensure a consistent and effective amount of medicine is maintained in the body.

Q: Can Tropharma be taken with antacids?

A: Official information suggests that concurrent use of antacids may affect the elimination time of erythromycin. However, these changes are generally considered unlikely to be of clinical importance, and regulatory contexts suggest no special precautions are necessary.

Q: Is Tropharma safe for teenagers or adolescents?

A: Tropharma is approved for use in children and is dosed by body weight for pediatric patients. Specific warnings apply primarily to infants and neonates. Adolescents are covered by dosing guidance for older children or adults in the regulatory documents.

Q: Does Tropharma interact with herbal remedies or vitamins?

A: The official interaction profile notes that the herbal remedy St John's Wort is to be avoided. Additionally, consumption of calcium-fortified foods (which can include supplements) near dosing time may interfere with the drug's absorption.

Q: How is Tropharma eliminated from the body?

A: In individuals with normal liver function, the medicine is primarily concentrated in the liver and then excreted in the bile. Only a small percentage of the active dose (less than 5%) is typically recovered in the urine.

Q: Why is Tropharma sometimes prescribed for conditions other than its main use?

A: Regulatory documents only establish the drug's approved use for bacterial infections. However, the medicine has been formally studied in research for potential alternative applications, as seen in the official research summaries detailing trials for conditions like Chronic Insomnia and Generalized Anxiety Disorder.

Q: Do I need to change my diet while taking Tropharma?

A: Official instructions state that the tablets are prescribed to be administered in a fasting state to ensure optimal absorption. Specific foods, such as grapefruit and dairy products, may also interfere with the absorption process.

Q: Can I stop taking Tropharma suddenly?

A: Regulatory information stresses the importance of taking the medication exactly as directed and completing the full course of therapy. Not completing the full course may decrease effectiveness and increase the likelihood of the target bacteria developing resistance.

Q: What are the signs of an allergic reaction to Tropharma?

A: Official drug information lists signs of a serious allergic reaction, or hypersensitivity, which can include hives, difficult breathing, swelling in the face, tongue, or throat, and a spreading rash.

Q: Does Tropharma require any special monitoring or blood tests?

A: Due to the potential for risks like hepatotoxicity (liver damage) and serious drug interactions, the official label may indicate the need for careful monitoring, which can include checks of liver enzymes (serum transaminase) or other values like creatine kinase (CK) levels.

Q: Is Tropharma considered a 'new' drug or has it been around for a while?

A: The active ingredient in Tropharma, Erythromycin Stearate, is a long-established medication. It was approved by the FDA Prior to January 1, 1982, indicating it is a long-established medication.

Q: Does Tropharma lose effectiveness over time?

A: The medicine's action is known to be limited by bacterial resistance. Not completing the full course of therapy increases the likelihood that bacteria will develop resistance and will not be treatable by the drug in the future.

Q: Does Tropharma affect my mood or mental state?

A: The official research summary includes studies for Generalized Anxiety Disorder, indicating potential effects on mood or anxiety levels are documented in clinical research. The medicine also interacts with certain central nervous system agents, such as benzodiazepines, which can result in side effects including drowsiness or confusion.

Q: Is Tropharma safe to use if I have high blood pressure?

A: While high blood pressure itself is not an absolute contraindication, the medicine can interact with certain calcium channel blockers, such as Verapamil, which are used to treat high blood pressure. This combination can result in effects like low blood pressure and a low heart rate.

Q: Does Tropharma interact with caffeine?

A: Regulatory resources note that Tropharma may inhibit the body's breakdown of caffeine. Patients may experience increased effects from caffeine, such as nervousness or sleeplessness. Therefore, limitations on intake may be indicated.

Q: Why do official documents use the term '[specific medical jargon]' to describe Tropharma?

A: Official documents use precise scientific terms to describe the drug's properties. For instance, it is called a macrolide antibiotic because of its chemical structure and a CYP3A4 inhibitor because of the specific way it affects the body’s metabolism of other medicines.

Q: Are there different brand names for the same medication as Tropharma?

A: Yes, the active ingredient, Erythromycin, is a generic medication. It is sold under various brand names in addition to its generic designation, according to official prescribing labels.

Q: When was Tropharma approved by the FDA (or similar agency)?

A: The active ingredient in Tropharma, Erythromycin Stearate, is a long-established medication. It was approved by the FDA Prior to January 1, 1982, indicating it is a legacy drug product.

Q: What is the risk of overdose with Tropharma?

A: Taking one extra dose is unlikely to cause serious harm but may increase temporary side effects. Official guidance states that if more than one extra dose is taken, a patient should seek contact with a healthcare professional immediately for advice on the risk of more serious effects.

How should Tropharma be stored and disposed of?

Storage Requirements

Official labeling requires Tropharma (Erythromycin/Erythromycin Stearate film-coated tablets) to be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). Permitted temperature excursions range from 15 C to 30 C (59 F to 86 F). The medicine must be stored and dispensed in a tight container to maintain the stability of the active ingredient and must always be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Tropharma should be disposed of through a dedicated drug take-back program when available. If a take-back program is not accessible, the product must be mixed with an undesirable substance, placed in a sealed bag or container, and discarded in the household trash. The medicine must not be flushed down a toilet or poured down a drain unless regulatory instructions explicitly permit it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tropharma found in:

A-Z Index: